In 1997, Boston Scientific signed an agreement with Cook and Angiotech Pharmaceuticals (nasdaq: ANPI - news - people ), under which Cook and Boston Scientific were granted co-exclusive rights to use paclitaxel to coat coronary stents.
In 1997, Angiotech Pharmaceuticals (nasdaq: ANPI - news - people ) granted Cook and Boston Scientific (nyse: BSX - news - people ) co-exclusive rights to use the drug paclitaxel to coat coronary stents.